To include your compound in the COVID-19 Resource Center, submit it here.

Marizomib: Additional Phase I data

Data from 36 patients with grade IV malignant glioma in an open-label, dose-escalation, North American Phase I trial showed that IV marizomib on days 1, 8 and 15

Read the full 289 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE